---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-114800"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:18:23.923442+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q3 2024 royalty revenue $60.5M (+6% YoY); net product sales $27.8M; net income $1.2M

## Summary
- Royalty revenue from GSK $60.5M, up 6% YoY; core royalty platform continued strong performance.
- US net product sales $19.7M (+68% YoY) driven by GIAPREZA $13.1M, XACDURO $4.3M, XERAVA $2.3M.
- Net income $1.2M ($0.02 basic EPS) vs $82.0M ($1.26) in Q3 2023; unfavorable $35.2M fair value change on Armata investment.
- XACDURO nominated for Prix Galien USA Award; zoliflodacin NDA submission expected early 2025.
- Cash and cash equivalents $260.6M; royalty and product sales receivables $91.1M as of Sep 30, 2024.

## SEC filing metadata
- accession: 0001104659-24-114800
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465924114800/0001104659-24-114800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465924114800/tm2427621d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-114800
- JSON: https://secwatch.observer/filing/0001104659-24-114800.json
- Plain text: https://secwatch.observer/filing/0001104659-24-114800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.